The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma 15 December 2020
IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough... Read more